Incyte (INCY) PT Lowered to $86 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St rises as Anthropic's IPO filing sharpens focus on AI trade
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $114.73 -0.85%
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 41
Rating Summary:
18 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 41
Join SI Premium – FREE
Morgan Stanley analyst Vikram Purohit lowered the price target on Incyte (NASDAQ: INCY) to $86.00 (from $93.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Kaiser Aluminum Corporation (KALU) PT Lowered to $127 at KeyBanc
- Coca-Cola (KO) PT Raised to $102 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
